Medtronic Vascular, Inc. appears in the linked FDA premarket approval records as the applicant for a group of stent systems spanning carotid, superficial femoral artery, iliac and iliac vein indications. The filings describe supplements to existing approvals, covering manufacturing and process validation changes, sterilization monitoring changes and labeling instructions. The records place the applicant at a Plymouth, Minnesota filing address, which is a correspondence detail in the FDA data and not a verified headquarters. [1][2][3]
Documented stent systems and their components
The Protégé RX Carotid Stent System is described in Medtronic's instructions for use as a self-expanding Nitinol stent intended for permanent implantation, pre-mounted on a 6 Fr, 0.014-inch rapid exchange delivery system, with the stent cut from a Nitinol tube in an open lattice design. FDA records list the related Protégé GPS and Protégé RX carotid stent systems under product code NIM, device class 3, with a cardiovascular advisory committee. [9][1]
EverFlex is recorded as a self-expanding peripheral stent system under product code NIP, classified as a superficial femoral artery stent. Visi-Pro is recorded as a balloon-expandable peripheral stent system under product code NIO, classified as an iliac stent. Abre is recorded as a venous self-expanding stent system under product code QAN, classified as an iliac vein stent. [2][4][3]
Dated supplement activity in the linked FDA records
Two 30-day notices decided on 2026-11-05 cover manufacturing and process validation changes for the delivery systems of the EverFlex and Protégé GPS self-expanding peripheral stent systems: P060001/S060 for Protégé GPS and Protégé RX, and P110023/S070 for EverFlex. Both were received on 2026-10-09 and carry the supplement reason of process change affecting manufacturer, sterilizer, packager or supplier. [1][2]
Earlier decisions address sterilization monitoring. P030045/S011 for Visi-Pro and P060001/S059 for Protégé GPS and Protégé RX were both received on 2026-09-17 and decided on 2026-10-16 as 30-day notices, each covering a sterilization monitoring change to reduce incubation time for the biological indicator used in external process challenge devices. [4][5]
P200026/S020 for the Abre Venous Self-expanding Stent System was received on October 2, 2026 and approved on October 30, 2026 as a special immediate-track supplement. The FDA approval statement describes a labeling change that adds user-disassembly instructions for the device and addresses manual deployment after partial stent deployment. The record identifies the change as a labeling supplement. [3]
How to read the collection counts
The supplied portfolio snapshot, retrieved 2026-11-20, links 13 premarket approval records for this applicant, all on the PMA pathway, with decision counts of seven OK30 and six APPR. The five-record sample shown separately contains four OK30 and one APPR decisions. These are counts of the supplied filings at that retrieval time, not measures of total company portfolio, sales or safety performance. [1][2][3][4][5]
Applicant identity and scope limits
The applicant name on each cited filing is Medtronic Vascular, Inc., with a Plymouth, Minnesota address in the FDA record. The Medtronic product page for the Protégé RX system carries Medtronic branding and a 2026 copyright notice, and the instructions for use identify Medtronic trademarks. The cited FDA records do not establish corporate ownership structure, headquarters or commercial availability beyond what these documents state. [1][10][9]









